Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Maria P. Sormani et al.
Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.
ANNALS OF NEUROLOGY
(2021)
Review
Multidisciplinary Sciences
Sebastian Stockmaier et al.
Summary: The spread of contagious pathogens is influenced by social interactions, with changes in behavior affecting disease transmission. Both humans and nonhuman animals exhibit pathogen-induced alterations in social behavior, highlighting the importance of understanding these effects for evolution and epidemiology.
Article
Immunology
Paul Bastard et al.
Summary: Patients with biallelic loss-of-function variants of AIRE, suffering from APS-1, produce autoantibodies that neutralize most type I interferons, leading to a significantly increased risk of life-threatening COVID-19 pneumonia. Research has shown that in APS-1 patients with these neutralizing autoantibodies, 86% developed COVID-19 pneumonia.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Medicine, General & Internal
Rohini Mathur et al.
Summary: The study found that some minority ethnic populations in England have higher risks of testing positive for SARS-CoV-2 and experiencing adverse COVID-19 outcomes compared to the White population, even after adjusting for sociodemographic, clinical, and household characteristics.
Article
Multidisciplinary Sciences
Eric Y. Wang et al.
Summary: COVID-19 patients show increased autoantibody reactivities against immunomodulatory proteins, which may affect immune function and lead to different clinical outcomes.
Article
Clinical Neurology
Amber Salter et al.
Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Review
Clinical Neurology
Mahdi Barzegar et al.
Summary: During the COVID-19 pandemic, patients with MS had a lower infection rate and did not significantly increase mortality rate after contracting the disease. The most common symptoms were fever, cough, and fatigue. Specific treatment methods may affect the hospitalization and mortality rates of patients.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Clinical Neurology
Celine Louapre et al.
Article
Multidisciplinary Sciences
Elizabeth J. Williamson et al.
Article
Multidisciplinary Sciences
Paul Bastard et al.
